Presentation 17,18
医学ネタが続きます。
Presentation 17
Convection-Enhanced Drug Delivery: Increased Efficacy and MRI Monitoring
(Y.Mardor, A.Ocherashivilli, D.Daniels, Y.Roth,) - 1 S.E.Maier,(3) O.Rahav,(2) Z.Lidar,(2) J.Zauberman(4) and, Z. Ram(2)
1 - The Advanced Technology Cntr
2 - Dept of Neurosurgery, Sourasky Medical Cntr
3 - Brigham and Women’s
4 - Dept of Neurosurgery, Sheba Medical Cntr
********************************************
Convection-enhanced drug delivery (CED) is an emerging technology for drug delivery into brain tissue that has shown great promise in patients with recurrent GBM (most aggressive brain tumors). Based on our and others clinical experience, CED appears to have a potential for playing a major role in brain tumor therapy and a variety of non-neoplastic CNS disorders.
Several multi-center phase Ⅱ/Ⅲ trials using CED have recently been initiated where hundreds of patients are treated for several diseases of the brain.
However, the main pitfall of this technology is the difficulty in achieving reproducible efficient convection and the inability to monitor its extent/evolution. We have previously reported (Cancer Res, 2001), the application of diffusion-weighted MRI for monitoring CED of Taxol. A full summary of that clinical study describes the high response rate observed in our patients(JNS, 2004).
Concomitantly to our in house clinical trials with Taxol, we are involved in Phase Ⅱ/Ⅲ CED trials with other company-sponsored drugs. The different response rates obtained for different drugs in the clinical experience published thus far, as well as our own personal experience, has triggered us to initiate a pre-clinical development program in an attempt to improve the effect/monitoring of convection.
Our results (Cancer Res, 2005) served as a basis for pending patents that can be applied for optimizing convection of various therapeutic agents, while enabling monitoring the progression of convection and making modifications in real time thus reducing possible toxicity resulting from the treatment.
**********************************************
GBM : glomerular basement membrane, 多形神経膠芽腫 ??
Neurosurgery 脳神経外科学
http://www.emporis.com/en/wm/cx/?id=101049
http://www.brighamandwomens.org/
oncology 腫瘍学、オンコロジー
**********************************************
Presentation 18
Solid Tumor Cancer Treatment Using Diffusing Alpha Emitters Radio Therapy – DART
Dr. Gideon Shichman Chairman & CEO
Althera Medical Ltd.
**********************************************
Althera Medical is a cancer therapeutic Pre-clinical Stage Company focused on the development and commercialization of a revolutionary cancer treatment modality – Diffusing Alpha-emitters Radio-Therapy (DART). Althera’s therapy is aimed at total eradication or significant de-bulking of solid tumors either prior or post adjuvant therapies. The company is targeting Non Small Cell Lung Cancer as well as a variety of Head & Neck tumors.
Althera Medical theory utilizes the highly efficient irradiation effect of high-energy alpha particles by dispersing short-lived alpha emitters, atom by atom, inside and in the close vicinity of the tumor lesion. In general, instead of the geometric targeting which characterizes all currently used irradiation methods (both External Beam Radiotherapy and Brachytherapy), Althera Medical’s DART relies on generic targeting, which preferentially applies the radiation to the tumor, regardless of its shape. This feature derivers from the role played by the tumor blood vessels in dispersing the alpha-emitting nuclides throughout its volume.
DART is utilizing a unique concept of recoiled implantation of. A small, flexible needle, specially coated with a minute quantity of Radium 224 atoms is percutaneously inserted into the tumor. The progeny isotopes of the Radium-224 source radionuclide are readily dispersed in the tumor by thermal diffusion and convection, creating a lethal ”destruction Zone” of 6-10 mm diameter in the tumor tissue.
Pre-clinical studies conducted on mice models have already demonstrated DART’s basic operational principle. The unprecedented results of these experiments are very promising, foretelling a tremendous impact on the future of Brachtherapy and solid cancer treatment for a variety of cancers.
********************************************
http://www.ilsi.org.il/companies_life_science_company.asp?ID=951
